R&D News | pharmaphorum

News

Takeda scores with polycythemia vera drug in phase 3 trial

A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.

News

Australia stands firm on 'no' to Alzheimer's drug Leqembi

Eisai and Biogen have been unable to persuade Australia's medicines regulator to approve their Alzheimer's therapy Leqembi with a narrower label.

News

GSK bows to Trump pressure and pauses diversity policies

GSK has joined a lengthening list of companies that have paused diversity, equity, and inclusion (DEI) targets under pressure from US President Trump.

News

AbbVie pays Gubra $350m upfront to enter obesity field

AbbVie has joined the ranks of pharma groups trying to develop weight-loss drugs, licensing an amylin agonist from Gubra in a $2.2bn-plus deal.

News

Scientists in a boat graphic from Owkin for ATLANTIS

Owkin launches ATLANTIS patient data mining project

Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.

News

Eikon Therapeutics chief executive Roger Perlmutter

Perlmutter's Eikon raises $351m in major financing round

Eikon has added to its already copious cash reserves with a $351m round for its expanding pipeline of cancer therapies.

Takeda scores with polycythemia vera drug in phase 3 trial

Australia stands firm on 'no' to Alzheimer's drug Leqembi

GSK bows to Trump pressure and pauses diversity policies

AbbVie pays Gubra $350m upfront to enter obesity field

Owkin launches ATLANTIS patient data mining project

Perlmutter's Eikon raises $351m in major financing round

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks